Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal melanoma
Tebentafusp Phase 3 randomized trial data subject of an oral presentation at
the American Association for Cancer Research (AACR) 2021 Annual Meeting
Cash position